Loading...
Lenvatinib as first-line therapy for recurrent hepatocellular carcinoma after liver transplantation: Is the current evidence applicable to these patients?
Liver transplantation (LT) is one of the leading curative therapies for hepatocellular carcinoma (HCC). Despite recent optimization of transplant selection criteria, including alpha-feto protein, HCC recurrence after LT is still the leading cause of death in these patients. During the last decades,...
Na minha lista:
| Udgivet i: | World J Transplant |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Baishideng Publishing Group Inc
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7708877/ https://ncbi.nlm.nih.gov/pubmed/33312891 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5500/wjt.v10.i11.297 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|